RESUMO
Introduction: HER-2/neu is a membrane protein and it is one of the determining prognostic factors of breast cancer
Objective: The aim of the study was to investigate the relationship between the expression of the HER-2 membrane protein and clinical- pathological parameters such as size: degree of the tumor differentiation, presence or absence of lymphovascular invasion and its relation with steroid hormone and P53 status in breast cancer patients
Materials and Methods: This descriptive study was done on 465 cases of breast cancers referred to two cancer centers in Gilan from 1980-1985. Patients' demographic data, pathological and type of clinical therapy were gathered from their medical charts. All membrane samples taken by biopsy were embedded in paraffin and stained by hematoxylin-eosin technique and were evaluation by a semi-quantitative method of immunohisto- chemistery for HER2 protein, P53 and steroidal receptor
Results: A total of 32% of breast cancer patients had positive HER2 protein. There was a positive correlation between HER2 protein and P53 protein expression [P=0.000]. There was a positive relationship between presence of HER2 protein and absence of steroid receptor with high-grade tumor [grade 3][P=0.3] and absence of HER2 and presence of steroid receptor with low-grade tumor [grade 1] [P=0.5]. There was no correlation between HER2 and lymphovascular invasion and size of tumor
Conclusion: In breast cancer patients, there is a positive correlation between presence of HER2 protein and degree of tumor differentiation and it also correlates with poor prognostic factors such as hormone receptor negativity and P53 positivity
RESUMO
Introduction: Mutation of the P53 gene is thought to stimulate cell growth and to be involved in the development and progression of tumors
Objective: The aim of this study was to survey the relationship of P53 with other clinic pathological parameters such as size of tumor, grade of malignancy, lymph vascular attacks, and also its correlation with the condition of steroid receptors in breast cancer patients [BCP]
Materials and Methods: The study samples were chosen from 465 BCPs who had breast surgery or excistonal biopsy. Immunohistochemistery method was applied for the detection of estrogen and progesterone receptor and HER2 and P53. According to hormone receptor status, cases were either hormone receptor positive [ER+ or PR+] or hormone receptor negative [ER- and PR-]. We divided patients into two groups: low grade instead of grade1, and high grade instead of grade 2 and 3
Results: 29.7% of our 465 cases were P53 positive. The mean age of P53negative cases was significantly more than P53 positive ones. [49.2 y/o vs. 46.7 y/o] P53 protein Expression correlated positively with HER2 protein expression. [P=0.000]. P53 negativity and hormone receptor positivity had a positive correlation with low-grade tumor [P=0.007]. There were no significant correlation between P53 and lymphovascular invasion and relapse and tumor size
Conclusion: Our results show that tumors of low malignant potential [grade1] have an immunophenotype of P53-, ER+, PR+, while high grade tumors [grade3] frequently express a P53+ and ER-, PR- phenotype. Negativity of P53 has a significant correlation with good prognostic factors like hormone receptor positive and low gradity, so evaluation of biologic marker of P53 is helpful to select the protocol of treatment in patients with equal stages